This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Serum measurements of testosterone, insulin-like growth
factor 1, and insulin-like growth factor binding protein-3 in
the diagnosis of prostate cancer among Korean men
Sung Kyu Hong, Byung Kyu Han, Jae Seung Jeong, Seong Jin Jeong, Ki Hyuk Moon, Seok Soo Byun, Sang Eun Lee
Department of Urology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea
Abstract
Aim: To investigate the relationships of serum testosterone, insulin-like growth factor (IGF)-1 and IGF-binding protein
(IGFBP)-3 levels with prostate cancer risk and also with known prognostic parameters of prostate cancer in Korean men
who received radical retropubic prostatectomy (RRP) for clinically-localized prostate
cancer. Methods: Serum levels of total testosterone, free testosterone, IGF-1 and IGFBP-3 were determined in 592 patients who subsequently received
prostate biopsy. Results were compared between patients who eventually received RRP for prostate cancer
(n = 159) and those who were not diagnosed with prostate cancer from biopsy (control group,
n = 433). Among the prostate cancer
only patients, serum hormonal levels obtained were analyzed in relation to serum prostate specific antigen (PSA),
pathological T stage and pathological Gleason
score. Results: Prostate cancer patients and the control group
demonstrated no significant differences regarding serum levels of total testosterone, free testosterone, IGF-1 and IGFBP-3
across the different age groups. Among the cancer
only patients, no significant associations were observed for serum
levels of total testosterone, free testosterone, IGF-1 and IGFBP-3 levels with pathological T stage, pathological Gleason
score and preoperative PSA. Conclusion:
Our data indicate that simple quantifications of serum testosterone and
IGF-1 along with IGFBP-3 levels might not provide useful clinical information in the diagnosis of clinically localized prostate
cancer in Korean men. Also, our results suggest that serum levels of testosterone, IGF-1 and IGFBP-3 might not be
significantly associated with known prognostic factors of clinically localized prostate cancer in Korean
men. (Asian J Androl 2008 Mar; 10: 207_213)
Keywords: prostate; prostate cancer; testosterone;
insulin-like growth factor; insulin-like growth factor-binding protein-3
Correspondence to: Dr Sang Eun Lee, Department of Urology, Seoul National University Bundang Hospital, 300, Gumi-dong,
Bundang-gu, Seongnam, Kyunggi-do 463-707, Korea.
Tel: +82-31-787-7341 Fax: +82-31-787-4057
E-mail: selee@snubh.org
Received 2007-01-30 Accepted 2007-04-20
DOI: 10.1111/j.1745-7262.2008.00296.x
1 Introduction
Prostate cancer is one of the most common male cancers
in developed countries. Meanwhile, in Asia where the risk
of prostate cancer has previously been known to be much lower, prostate cancer incidence is currently rising rapidly [1].
Factors responsible for such dramatic change might include aging population,
westernization of lifestyle, and certainly widespread usage of prostate-specific antigen (PSA) testing. Still, huge differences exist in prostate cancer incidences
among Asian and developed countries. Such phenomenon might be a result of an interaction of genetic and
environmental factors, which in turn would affect hormonal milieu. As racial variations in the levels of various hormones
have been reported to exist, the significances of hormonal system markers regarding prostate cancer might
also be different for those in Asian and developed
countries [2, 3].
After observations that certain hormones, such as
testosterone and insulin-like growth factor-1 (IGF-1),
can affect prostate cancer cell growth, several
researchers have investigated the significances of these hormones
regarding risk and/or prognosis of prostate cancer in
European and American. Certainly, the responsiveness
of prostate cancer to hormonal therapy supports the
view that testosterone might indeed play an important
role in the pathogenesis of prostate cancer. However,
conflicting results are reported on the potential
diagnostic and/or prognostic value of serum testosterone. As
for IGF axis, inconsistent data have also been reported
on its value in assessing biological risk and/or prognosis
for prostate cancer. Meanwhile, a paucity of published
data exists on the significances of serum testosterone,
IGF-1 and IGF-binding protein (IGFBP)-3 levels
regarding risk and prognosis of prostate cancer in Asian men.
Therefore, we investigated the relationship of serum
testosterone, IGF-1 and IGFBP-3 levels with prostate
cancer risk and also with known prognostic parameters
of prostate cancer in Korean men who received radical
retropubic prostatectomy (RRP) for clinically-localized
prostate cancer.
2 Materials and methods
2.1 Study design
This was a single institutional prospective study
performed with upon approval from our institutional
review board. Between May 2005 and June 2006, 616
consecutive patients with high serum PSA level
(¡Ý 3.0 ng/mL), a suspicious digital rectal exam, and/or hypoechoic
lesion observed via transrectal ultrasound who were
evaluated at our department were recruited. To be
eligible for enrolment in our study, patients had to have
Eastern Cooperative Oncology Group-performance status of one or less and no other medical problem, which
might preclude them from having radical prostatectomy if
indicated. After obtaining informed consent, blood samples
were taken before any prostatic manipulation, and serum
levels of total testosterone, free testosterone, IGF-1 and
IGFBP-3 were analyzed. All patients subsequently
underwent transrectal ultrasound-guided prostate biopsy with
at least 12 cores taken.
2.2 Subjects
Of the 616 patients, 183 (29.7%) were diagnosed
with prostate cancer from biopsy. Of the 183 cancer
patients, 159 eventually underwent RRP for
clinically-localized prostate cancer without receiving any hormonal
or radiation treatment preoperatively. Among the patients
diagnosed with prostate cancer from biopsy, we only
included these 159 patients who received radical
prostatectomy in our analysis because no exact pathologic
staging or Gleason score could be obtained without RRP
specimen. The radical prostatectomy specimens were
processed by whole-mount technique, and examined by
a single pathologist at our institution. Meanwhile, 433
patients who were not diagnosed with prostate cancer
from biopsy were designated as the control group.
2.3 Hormonal assay
Serum samples for hormonal evaluation were obtained
via cubital vein puncture between 7:30 am and
10:00 am prior to prostate biopsy. Blood samples were collected
into Z Serum Separation Clot Activator 8 mL tubes,
centrifuged (× 1 500 g) at room temperature for 7 min, and
immediately stored at a temperature of _80ºC in
polypropylene cryopreservation vials. The PSA level was
determined by immunoradiometric assay using the
125I-PSA IRMA kit (Institute of Isotopes, Budapest, Hungary). The
total and free testosterone levels were, respectively,
measured by chemiluminescent microparticle immunoassay
using Architect Testosterone Reagent kit (Abbott Laboratories, Chicago, IL, USA) and radioimmunoassay
using Coat-A-Count Free Testosterone kit (DPC, Los
Angeles, CA, USA). Serum IGF-1 and IGFBP-3 were
quantified by immunoradiometric assay using IRMA IGF-1
kit (Immunotech, Marseille, France) and IRMA
IGFBP-3 kit (Immunotech, Marseille, France), respectively. Each
sample was assayed for each analyte in duplicate, and
the average of two values was taken for analysis.
Coefficient of variation was less than 8% for each assay.
2.4 Statistical analysis
The SPSS software package version 11.0 (SPSS, Chicago, IL, USA) was used for statistical analysis.
Differences in two groups of subjects regarding various
parameters were analyzed via Mann-Whitney test.
Distributions of categorical variables were compared by
χ2-test. Correlations of continuous variables were
analyzed using the Spearman rank procedure.
P < 0.05 was considered significant.
3 Results
3.1 Baseline characteristics
Principal characteristics of prostate cancer patients
and control group included in our study are as listed in
Table 1. Median ages of prostate cancer patients and
control group were 65 years and 64 years, respectively,
demonstrating no significant difference (P = 0.711). For
the two groups, median PSA values were 8.9 ng/mL
and 4.9 ng/mL (P < 0.001), respectively. Median
prostate volumes as determined from transrectal ultrasound
were 41.3 mL and 43.5 mL, respectively
(P = 0.358). Among the cancer patients, the most common
pathologic Gleason score assessed from RRP specimens was
7 (in 61.6%), those with ¡Ý pT3 tumors were 22%, and
those with involvement of surgical margin were 21.4%.
3.2 Comparison of prostate cancer patients and control
group
As can be seen in Table 2, prostate cancer patients
and the control group demonstrated no significant
differences regarding serum levels of total testosterone
(P = 0.367), free testosterone
(P = 0.284), IGF-1
(P = 0.542) and IGFBP-3
(P = 0.756) across the different age groups. Serum total and free testosterone
levels appeared to decrease with age, but showed no
significant correlation with age in both cancer patients and
the control group (all P-values > 0.05). Meanwhile,
serum IGF-1 and IGFBP-3 also demonstrated trends of
having inverse correlations with age in both cancer
patients and the control group, but not being statistically
significant (all P-values > 0.05). Serum total and free
testosterone showed no significant correlation with
either serum IGF-1 or IGFBP-3 levels in both cancer
patients and the control group (all P-values > 0.05).
3.3 Analysis of prostate cancer patients only
When prostate cancer only patients were divided into
the two groups according to testosterone levels (group 1,
those with lowest quartile of serum total testosterone
level distribution; group 2, the other remaining patients),
group 1 consisted of those with serum total testosterone
level of 3.4 ng/mL or lower (n = 39), whereas group 2
consisted of 120 patients with testosterone levels higher
than 3.4 ng/mL (Table 3). The distributions of age
(P = 0.432), tumor stage
(P = 0.368), pathologic Gleason score
(P = 0.735), serum PSA
(P = 0.258) and margin positivity
(P = 0.387) were not significantly different
between the two groups. Meanwhile, serum IGF-1 levels
were correlated with IGFBP-3 levels (P < 0.001). As
shown in Table 4, there was no significant association
between IGF-1 and IGFBP-3, respectively, with PSA levels
(P = 0.454, P = 0.737), tumor stage
(P = 0.631, P = 0.844), pathological Gleason score
(P = 0.585, P = 0.578) and margin positivity
(P = 0.733, P = 0.898)
among the patients with prostate cancer.
4 Discussion
Significance of testosterone has been discussed in
several studies of patients, mostly European and American,
with prostate cancer. Iversen et al. [4] report that
pretreatment low serum testosterone correlates with
decreased survival for prostate cancer. Furthermore,
Schatzl et al. [5, 6] report that low serum testosterone is
associated with higher tumor microvessel and androgen receptor density as well as with higher Gleason
scores in patients with newly diagnosed prostate cancer.
So far, several published reports have indicated that low
testosterone levels are associated with poor outcomes
for patients with prostate cancer. However, most such
reports are based upon studies that include limited
numbers of subjects. Zagars et al. [7] claim that high rather
than low pretreatment serum testosterone significantly
correlates with metastatic relapse after radiation
treatment for prostate cancer. As in the present study, Fodstad
et al. [8] report from their study of 370 patients with
newly diagnosed stage T1 to T3pN0M0 prostate cancer
that no statistically significant association was found for
serum values of testosterone with local tumor stage,
Gleason score or PSA. Meanwhile, although Teloken
et al. [9] reported that low serum testosterone is
associated with higher risk of positive surgical margins in RRP
specimen, low testosterone levels were not observed to
be significantly associated with higher Gleason scores
or pathological stage. Also, despite the fact that serum
testosterone levels appeared to be predictive of local
tumor stage in a recent study of 82 Japanese men who
received radical prostatectomy, serum testosterone
levels actually showed no significant association with
serum PSA level, Gleason score or even PSA recurrence
rate [10].
As for IGF, a great amount of attention was initially
focused on the potential association of IGF axis and
prostate cancer primarily because of the published results of
prospective studies suggesting a certain relationship
between serum IGF-1/IGFBP-3 levels and risk of
developing prostate cancer. Mantzoros
et al. [11] report that elevated serum IGF-1 levels might increase the risk of
prostate cancer. Chan et al. [12]
state that both IGF-1 and IGFBP-3 might predict the risk of developing
advanced prostate cancer while not being much use in
screening patients for early stage prostate cancer. Oliver
et al. [13] observed that risk of prostate cancer increased
across quartiles of IGF-1 and association of IGF with
prostate cancer risk were stronger for advanced cases.
By performing meta-regression analysis, Renehan
et al. [14] found that increased circulating concentration of
IGF-1 is associated with increased risk of prostate cancer.
In contrast, Woodson et al. [15] observed no evidence
from a prospective study that would support a causal
association between serum IGF-1 or IGFBP-3 and the
risk of prostate cancer. Janssen
et al. [16] show that measurement of serum levels of IGF-1 and/or IGFBP-3
in addition to PSA does not improve the identification of
men at high risk of developing early stage prostate cancer.
Finne et al. [17] quantified IGF-I and IGFBP-3 serum
levels in 665 consecutive men undergoing prostate
biopsies and stated that association between serum IGF-1
and prostate cancer risk was not significant. Ismail
et al. [18] investigated 652 men undergoing prostate biopsies
and conclude that serum IGF-1 and IGFBP-3 do not
predict the results of prostate biopsy. Marszalek
et al. [19] report from their study of 156 men with prostate cancer
and 271 controls that serum IGF-1 levels do not
correlate with serum PSA, Gleason score and number of
positive biopsy cores. Despite the fact that these data were
obtained from studying European and American, they are
in line with results of our study as we also observed that
serum IGF-1 and IGFBP-3 levels did not correlate with
serum PSA levels, tumor stage and pathologic Gleason
score.
Although most previous reports indicate that low
serum testosterone might be somehow associated with
poor prognosis for prostate cancer, we observed no
evidence to support such an idea in the current study
of Korean men with prostate cancer. Racial disparity
might contribute to this discrepancy. Various
investigators have suggested that racial variations in serum
levels of hormones, including testosterone along with
its derivatives, exist and that hormonal difference might
contribute to differences in prostate cancer risks among
different races [3]. Some have shown that Asian men
have higher serum total testosterone with lower dihydrotestosterone levels than European and
American [2]. Furthermore, the fact that available data
regarding the significance of testosterone in relation to
prostate cancer are inconsistent suggests that serum
testosterone level might not be an ideal diagnostic or
prognostic marker for prostate cancer irrespective of
the actual association of testosterone with prostate
cancer's development and/or aggressiveness. Because
so many factors, including age, general condition,
timing and method of assaying, influence serum total and
free testosterone levels, application of such hormonal
marker testing to clinical practice might not be ideal.
Meanwhile, although serum testosterone level did not
demonstrate any significant correlations with known
prognostic parameters of prostate cancer in the present
study, it would be inappropriate to completely deny the
potential significance of testosterone in relation to the
development and/or progression of prostate cancer
considering the data currently available in the published
literature. However, simple assay of total and free
testosterone levels might not provide much information,
at least for Asian men with prostate cancer, as shown
by our data.
As shown in our study, several previous reports
indicated that serum levels of IGF-1 and IGFBP-3 do
not have significant correlations with known
prognostic parameters of prostate cancer [16_19].
This absence of association should not be immediately
translated into a belief that IGF axis as a whole is not related
to pathogenesis or progression of prostate cancer. The
situation might well be different regarding local tissue
expression as decreased local expression of IGFBP-3
is associated with higher grade prostate cancers [18].
Another possible explanation for our negative finding
might be that normal circulating IGF-1 levels might exert
a greater effect on malignant than normal prostatic
tissues. Another member of the IGF axis might be a
better prognostic marker for prostate cancer: others
have reported that serum IGFBP-2, which is the main
IGFBP produced by prostate epithelial cells, is inversely
associated with prostate cancer aggressiveness and
progression [20]. Still, IGF-1 and IGFBP-3 might not be
useful clinical parameters in assessing risk or prognoses
of prostate cancer in Asian men.
One of the potential limitations of the present study
is the makeup of the control group. Despite the fact
that all subjects included in the control underwent 12
or more core transrectal ultrasound-guided biopsies and
had negative results, the possibility of prostate cancer
existence could not be completely excluded in the
control group. However, PSA values of the control group
were significantly lower compared with cancer patients.
Also, because of the short duration of follow-up, we
could not assess the impact of hormones studied on
long-term prognoses of patients, which we will analyze
in future.
Our data indicate that simple quantifications of
serum testosterone and IGF-1 along with IGFBP-3 levels
might not provide useful clinical information on the
diagnosis of clinically localized prostate cancer in Korean
men. Also, our results suggest that serum levels of
testosterone, IGF-1 and IGFBP-3 might not be
significantly associated with known prognostic factors of
clinically localized prostate cancer in Korean men.
References
1 Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T,
Hara N. Outcomes of locally advanced prostate cancer: a
single institution study of 209 patients in Japan. Asian J
Androl 2006; 8: 555_61.
2 Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher
RP, West DW, et al. Serum androgens and sex
hormone-binding globulins in relation to lifestyle factors in older
African-American, white, and Asian men in the United States and
Canada. Cancer Epidemiol Biomarkers Prev 1995; 4: 735_41.
3 Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci
E. Racial variation in prostate cancer incidence and in
hormonal system markers among male health professionals. J
Natl Cancer Inst 2000; 92: 2009_17.
4 Iversen P, Rasmussen F, Christensen IJ. Serum testosterone
as a prognostic factor in patients with advanced prostatic
carcinoma. Scand J Urol Nephrol Suppl 1994; 157: 41_7.
5 Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer
G, Haitel A, et al. High-grade prostate cancer is associated
with low serum testosterone levels. Prostate 2001; 47: 52_8.
6 Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M,
Haidinger G, et al. Associations of serum testosterone with
microvessel density, androgen receptor density and androgen
receptor gene polymorphism in prostate cancer. J Urol 2003;
169: 1312_5.
7 Zagars GK, Pollack A, von Eschenbach AC. Serum
testosteronea significant determinant of metastatic relapse for
irradiated localized prostate cancer. Urology 1997; 49: 327_34.
8 Fodstad P, Bjørro T, Torlakovic G, Fossa SD. No association
of serum gonadal or pituitary hormones with prognostic
parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol
2002; 168: 1188_92.
9 Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP,
Graziottin TM. Low serum testosterone levels are associated
with positive surgical margins in radical retropubic
prostate-ctomy: hypogonadism represents bad prognosis in prostate
cancer. J Urol 2005; 174: 2178_80.
10 Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M,
Komiya A, et al. Pretreatment serum testosterone level as a
predictive factor of pathological stage in localized prostate
cancer patients treated with radical prostatectomy. Eur Urol
2005; 47: 308_12.
11 Mantzoros CS, Tzonou A, Signorello LB, Stampfer M,
Trichopoulos D, Adami HO. Insulin-like growth factor 1 in
relation to prostate cancer and benign prostatic hyperplasia.
Br J Cancer 1997; 76: 1115_8.
12 Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak
M, et al. Insulin-like growth factor I (IGF-I) and IGF binding
protein-3 as predictors of advanced-stage prostate cancer. J
Natl Cancer Inst 2002; 94: 1099_106.
13 Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt
D, et al. Screen-detected prostate cancer and the insulin-like
growth factor axis: results of a population-based case-control
study. Int J Cancer 2004; 108: 887_92.
14 Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet
SM, Egger M. Insulin-like growth factor (IGF)-1, IGF
binding protein-3, and cancer risk: systemic review and
meta-regression analysis. Lancet 2004; 363: 1346_53.
15 Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR,
Virtamo J, et al. Serum insulin-like growth factor I: tumor
marker or etiologic factor? A prospective study of prostate
cancer among Finnish men. Cancer Res 2003; 63: 3991_4.
16 Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik
RH, Roobol MJ, et al. Circulating free insulin-like growth
factor (IGF)-I, total IGF-1, and IGF binding protein-3 levels
do not predict the future risk to develop prostate cancer:
results of a case-control study involving 201 patients within a
population-based screening with a 4-year interval. J Clin
Endocrinol Metab 2004; 89: 4391_6.
17 Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L,
Rannikko S, et al. Insulin-like growth factor I is not a
useful marker of prostate cancer in men with elevated levels of
prostate-specific antigen. J Clin Endocrinol Metab 2000; 85: 2744_7.
18 Ismail HA, Pollak M, Behlouli H, Tanguay S, Begin LR,
Aprikian AG. Serum insulin-like growth factor (IGF)-1 and
IGF-binding protein-3 do not correlate with Gleason score or
quantity of prostate cancer in biopsy samples. BJU Int 2003;
92: 699_702.
19 Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald
M, Madersbacher S. Insulin-like growth factor 1, chromogranin
A and prostate specific antigen serum levels in prostate cancer
patients and controls. Eur Urol 2005; 48: 34_9.
20 Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J,
et al. Association of preoperative plasma levels of insulin-like
growth factor I and insulin-like growth factor binding
proteins-2 and -3 with prostate cancer invasion, progression, and
metastasis. J Clin Oncol 2002; 20: 833_41.
|